0ILL Relative Valuation - Laboratorios Farmaceuticos ROVI SA

Watchlist Manager

Watchlist

Price: 81.4 EUR -1.03% Market Closed

Market Cap: €150.4m

	Laboratorios Farmaceuticos ROVI SA LSE:0ILL	ES
	Growthpoint Properties Australia Ltd OTC:GRWPF	AU

Multiples-Based Value

0ILL price has not been updated for more than 4 years. This may indicate that the stock has been delisted.

The Multiples-Based Value of one 0ILL stock under the Base Case scenario is 68.05 EUR. Compared to the current market price of 81.4 EUR, Laboratorios Farmaceuticos ROVI SA is Overvalued by 16%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is relative valuation?

How is Multiples-Based Value calculated?

0ILL Multiples-Based Value

Base Case

Overvaluation 16%

Multiples-Based Value

Price €81.4

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
ES		Laboratorios Farmaceuticos ROVI SA LSE:0ILL	4.2B EUR	5.6	29.5	19.2	22.3
US		Eli Lilly and Co NYSE:LLY	875.9B USD	13.5	42.7	28.8	30.7
US		Johnson & Johnson NYSE:JNJ	580.2B USD	6.1	21.5	14.9	18.3
UK		AstraZeneca PLC LSE:AZN	232B GBP	5.2	30	16.6	23.4
CH		Roche Holding AG SIX:ROG	248.4B CHF	4.1	19.7	11.6	13.1
US		Merck & Co Inc NYSE:MRK	299.1B USD	4.5	16	10	12.1
CH		Novartis AG SIX:NOVN	236.4B CHF	5.1	20.7	12.8	16.5
IE	E	Endo International PLC LSE:0Y5F	244.4B USD	105.4	-83.6	386.8	970
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.4	10.2	7.6	8.9
US		Pfizer Inc NYSE:PFE	158.2B USD	2.5	19.9	7.7	10.2
US		Bristol-Myers Squibb Co NYSE:BMY	119.4B USD	2.4	16.6	7	8.7

				Revenue Growth	P/S to Growth
ES		Laboratorios Farmaceuticos ROVI SA LSE:0ILL	Average P/S: 14.4 5.6	13%	0.4
US		Eli Lilly and Co NYSE:LLY	13.5	19%	0.7
US		Johnson & Johnson NYSE:JNJ	6.1	7%	0.9
UK		AstraZeneca PLC LSE:AZN	5.2	N/A	N/A
CH		Roche Holding AG SIX:ROG	4.1	4%	1
US		Merck & Co Inc NYSE:MRK	4.5	5%	0.9
CH		Novartis AG SIX:NOVN	5.1	5%	1
IE	E	Endo International PLC LSE:0Y5F	105.4	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.4	1%	3.4
US		Pfizer Inc NYSE:PFE	2.5	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.4	-5%	N/A

				Earnings Growth	PEG
ES		Laboratorios Farmaceuticos ROVI SA LSE:0ILL	Average P/E: 22.7 29.5	22%	1.3
US		Eli Lilly and Co NYSE:LLY	42.7	32%	1.3
US		Johnson & Johnson NYSE:JNJ	21.5	7%	3.1
UK		AstraZeneca PLC LSE:AZN	30	26%	1.2
CH		Roche Holding AG SIX:ROG	19.7	14%	1.4
US		Merck & Co Inc NYSE:MRK	16	14%	1.1
CH		Novartis AG SIX:NOVN	20.7	14%	1.5
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -83.6	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.2	1%	10.2
US		Pfizer Inc NYSE:PFE	19.9	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	16.6	16%	1

				EBITDA Growth	EV/EBITDA to Growth
ES		Laboratorios Farmaceuticos ROVI SA LSE:0ILL	Average EV/EBITDA: 47.5 19.2	19%	1
US		Eli Lilly and Co NYSE:LLY	28.8	22%	1.3
US		Johnson & Johnson NYSE:JNJ	14.9	2%	7.5
UK		AstraZeneca PLC LSE:AZN	16.6	13%	1.3
CH		Roche Holding AG SIX:ROG	11.6	6%	1.9
US		Merck & Co Inc NYSE:MRK	10	3%	3.3
CH		Novartis AG SIX:NOVN	12.8	5%	2.6
IE	E	Endo International PLC LSE:0Y5F	386.8	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	7.6	1%	7.6
US		Pfizer Inc NYSE:PFE	7.7	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
ES		Laboratorios Farmaceuticos ROVI SA LSE:0ILL	Average EV/EBIT: 103.1 22.3	21%	1.1
US		Eli Lilly and Co NYSE:LLY	30.7	22%	1.4
US		Johnson & Johnson NYSE:JNJ	18.3	6%	3.1
UK		AstraZeneca PLC LSE:AZN	23.4	21%	1.1
CH		Roche Holding AG SIX:ROG	13.1	6%	2.2
US		Merck & Co Inc NYSE:MRK	12.1	6%	2
CH		Novartis AG SIX:NOVN	16.5	9%	1.8
IE	E	Endo International PLC LSE:0Y5F	970	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	8.9	2%	4.4
US		Pfizer Inc NYSE:PFE	10.2	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	8.7	-7%	N/A

Laboratorios Farmaceuticos ROVI SA
LSE:0ILL

Multiples-Based Value

Valuation Multiples

Multiples Across Competitors

0ILL Competitors Multiples
Laboratorios Farmaceuticos ROVI SA Competitors

See Also

Company

Help

Tools

Stocks

Laboratorios Farmaceuticos ROVI SA LSE:0ILL

Multiples-Based Value

Valuation Multiples

Multiples Across Competitors

0ILL Competitors Multiples Laboratorios Farmaceuticos ROVI SA Competitors

See Also

Company

Help

Tools

Stocks

Laboratorios Farmaceuticos ROVI SA
LSE:0ILL

0ILL Competitors Multiples
Laboratorios Farmaceuticos ROVI SA Competitors